Early tumor shrinkage as an “on-treatment” clinical predictor of long-term outcome in solid organ cancers

CC BY-NC-ND 4.0 · Indian J Med Paediatr Oncol 2016; 37(04): 306
DOI: 10.4103/0971-5851.195733

LETTERS TO EDITOR

Authors

Pratishtha Banga Chaudhari

Medical Officer, NMMC - Health Department, UHP, Airoli, New Mumbai, Maharashtra, India

References
1 Modulation of fluorouracil by leucovorin in patients with advanced colorectal cancer: Evidence in terms of response rate. Advanced Colorectal Cancer Meta-Analysis Project. J Clin Oncol 1992;10:896-903.
2 Tang Y, Bycott P, Akerborg O, Jönsson L, Negrier S, Chen C. Interpreting overall survival results when progression-free survival benefits exist in today's oncology landscape: A metastatic renal cell carcinoma case study. Cancer Manag Res 2014;6:365-71.
3 Giessen C, Laubender RP, Fischer von Weikersthal L, Schalhorn A, Modest DP, Stintzing S, et al. Early tumor shrinkage in metastatic colorectal cancer: retrospective analysis from an irinotecan-based randomized first-line trial. Cancer Sci 2013;104:718-24.